Kynurenines and Mitochondrial Disturbances in Multiple Sclerosis

Area of Science:

• Neuroimmunology
• Neuroscience
• Biochemistry

Background:

• Multiple sclerosis (MS) is a chronic autoimmune CNS disease involving inflammation, demyelination, and neurodegeneration.
• The kynurenine pathway (KP) metabolizes tryptophan into neuroactive compounds, with its dysregulation central to MS pathology.
• Inflammatory cytokines activate KP, producing neuroprotective (kynurenic acid, KYNA) and neurotoxic (quinolinic acid, QUIN) metabolites.

Purpose of the Study:

• To review the role of kynurenine pathway dysregulation in multiple sclerosis across different disease stages.
• To integrate current understanding of KP mechanisms contributing to neurodegeneration in MS.
• To identify potential biomarkers and therapeutic targets for MS based on KP modulation.

Main Methods:

• Literature review integrating current understanding of KP dysregulation in MS.
• Analysis of KP metabolite profiles in relation to disease progression and severity.
• Examination of mitochondrial dysfunction and oxidative stress links to KP activity in MS.

Main Results:

• Heightened KP activity in Relapsing-Remitting MS (RRMS) correlates with inflammation and increased KYNA production.
• Secondary Progressive MS (SPMS) and Primary Progressive MS (PPMS) show a shift towards a neurotoxic KP profile with elevated QUIN.
• Increased QUIN exacerbates excitotoxicity, oxidative stress, and mitochondrial dysfunction, worsening neurodegeneration and disability.

Conclusions:

• KP dysregulation significantly contributes to neurodegeneration and disability progression in MS.
• Progressive MS stages are characterized by a shift towards neurotoxic KP metabolism.
• Targeting KP metabolism to restore balance and reduce neurotoxicity presents a promising therapeutic strategy for MS.